Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.3.2 to the revisions section. Deleted Revision: v3.2.0 from the revisions history.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoved an administrative notice about government funding and operating status. The content now focuses on the study details and locations.SummaryDifference0.3%

- Check42 days agoChange DetectedNew screenshot indicates minor text edits and formatting adjustments with no changes to the core study details, interventions, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%

- Check71 days agoChange DetectedAdded a new reference for Nivolumab plus ipilimumab in advanced melanoma and updated the page version to v3.1.0; removed a closely related Genetics Information Center entry and older version, effectively replacing the reference with an updated citation. Overall, bibliographic updates with minor versioning, no other substantive content changes.SummaryDifference0.5%

- Check85 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1; the 'Back to Top' element has been removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.